In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance and streaming services. He is passionate about language and technology, and has been an avid writer/reader of ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Forbes contributors publish independent expert analyses and insights. Amir is Founder of AI unicorn Avathon & Boeing/SC JV, SkyGrid. Recently, a friend asked me a question that's been floating around ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Using Science to Improve the BLM Wild Horse and Burro Program: A Way Forward reviews the science that underpins the Bureau of Land Management's oversight of free-ranging horses and burros on federal ...

We examine how AI is changing the future of work — and how, in many ways, that future is already here. Every tech company you can think of is jumping on the generative AI bandwagon and touting new ...

Starting in January, Medicare will test out an artificial intelligence (AI) pilot program to decide whether patients get certain procedures covered or not. The Centers for Medicare & Medicaid Services ...